A case of dramatic reduction in cancer-associated thrombus following initiation of pembrolizumab in patient with a poor performance status and PD-L1+ lung adenocarcinoma harboring CCDC6–RET fusion gene and NF1/TP53 mutations

Takamasa Nakasuka; Kadoaki Ohashi; Hiromi Watanabe; Toshio Kubo; Shingo Matsumoto; Koichi Goto; Katsuyuki Hotta; Yoshinobu Maeda; Katsuyuki Kiura

doi:10.1016/j.lungcan.2021.03.022

A case of dramatic reduction in cancer-associated thrombus following initiation of pembrolizumab in patient with a poor performance status and PD-L1⁺ lung adenocarcinoma harboring CCDC6–RET fusion gene and NF1/TP53 mutations

Takamasa Nakasuka, Kadoaki Ohashi, Hiromi Watanabe, Toshio Kubo, Shingo Matsumoto, Koichi Goto, Katsuyuki Hotta, Yoshinobu Maeda, Katsuyuki Kiura

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

Abstract

Objectives: Pembrolizumab is a standard treatment for non-small cell lung cancer (NSCLC) with high-PD-L1 expression; however, its effect is dismal in patients with poor physical condition. Additionally, the effect of immunotherapy is generally limited in NSCLC harboring driver mutations such asEGFR, ALK, or RET gene aberrations. Results: We report the beneficial effect of pembrolizumab in a patient with poor performance status and PD-L1+ lung adenocarcinoma with theCCDC6–RET fusion gene and co-occurring NF1/TP53 mutations, complicated by multiple cancer-associated thrombi and respiratory failure. Conclusions: Further studies are warranted to establish the role of co-occurring NF1/TP53 mutations as a positive predictive biomarker for pembrolizumab in NSCLC harboring RET fusion genes.

Original language	English
Pages (from-to)	1-4
Number of pages	4
Journal	Lung Cancer
Volume	156
DOIs	https://doi.org/10.1016/j.lungcan.2021.03.022
Publication status	Published - Jun 2021

ASJC Scopus subject areas

Oncology
Pulmonary and Respiratory Medicine
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.lungcan.2021.03.022

Fingerprint

Dive into the research topics of 'A case of dramatic reduction in cancer-associated thrombus following initiation of pembrolizumab in patient with a poor performance status and PD-L1⁺ lung adenocarcinoma harboring CCDC6–RET fusion gene and NF1/TP53 mutations'. Together they form a unique fingerprint.

Cite this

Nakasuka, T., Ohashi, K., Watanabe, H., Kubo, T., Matsumoto, S., Goto, K., Hotta, K., Maeda, Y., & Kiura, K. (2021). A case of dramatic reduction in cancer-associated thrombus following initiation of pembrolizumab in patient with a poor performance status and PD-L1⁺ lung adenocarcinoma harboring CCDC6–RET fusion gene and NF1/TP53 mutations. Lung Cancer, 156, 1-4. https://doi.org/10.1016/j.lungcan.2021.03.022

A case of dramatic reduction in cancer-associated thrombus following initiation of pembrolizumab in patient with a poor performance status and PD-L1⁺ lung adenocarcinoma harboring CCDC6–RET fusion gene and NF1/TP53 mutations. / Nakasuka, Takamasa; Ohashi, Kadoaki; Watanabe, Hiromi et al.
In: Lung Cancer, Vol. 156, 06.2021, p. 1-4.

Research output: Contribution to journal › Article › peer-review

Nakasuka, T, Ohashi, K, Watanabe, H, Kubo, T, Matsumoto, S, Goto, K, Hotta, K , Maeda, Y & Kiura, K 2021, 'A case of dramatic reduction in cancer-associated thrombus following initiation of pembrolizumab in patient with a poor performance status and PD-L1⁺ lung adenocarcinoma harboring CCDC6–RET fusion gene and NF1/TP53 mutations', Lung Cancer, vol. 156, pp. 1-4. https://doi.org/10.1016/j.lungcan.2021.03.022

@article{1d264bd065984cfbbde279053521df72,

title = "A case of dramatic reduction in cancer-associated thrombus following initiation of pembrolizumab in patient with a poor performance status and PD-L1+ lung adenocarcinoma harboring CCDC6–RET fusion gene and NF1/TP53 mutations",

abstract = "Objectives: Pembrolizumab is a standard treatment for non-small cell lung cancer (NSCLC) with high-PD-L1 expression; however, its effect is dismal in patients with poor physical condition. Additionally, the effect of immunotherapy is generally limited in NSCLC harboring driver mutations such asEGFR, ALK, or RET gene aberrations. Results: We report the beneficial effect of pembrolizumab in a patient with poor performance status and PD-L1+ lung adenocarcinoma with theCCDC6–RET fusion gene and co-occurring NF1/TP53 mutations, complicated by multiple cancer-associated thrombi and respiratory failure. Conclusions: Further studies are warranted to establish the role of co-occurring NF1/TP53 mutations as a positive predictive biomarker for pembrolizumab in NSCLC harboring RET fusion genes.",

author = "Takamasa Nakasuka and Kadoaki Ohashi and Hiromi Watanabe and Toshio Kubo and Shingo Matsumoto and Koichi Goto and Katsuyuki Hotta and Yoshinobu Maeda and Katsuyuki Kiura",

note = "Funding Information: This research received a specific grant from JSPS Grants-in-Aid for Scientific Research [Scientific Research (C): KAKEN 19K08625 to K. Ohashi and K. Kiura], and JSPS Grants-in-Aid for Scientific Research [Scientific Research (B): KAKEN 19H03667 to K. Ohashi and K. Kiura]. Publisher Copyright: {\textcopyright} 2021 Elsevier B.V.",

year = "2021",

month = jun,

doi = "10.1016/j.lungcan.2021.03.022",

language = "English",

volume = "156",

pages = "1--4",

journal = "Lung Cancer",

issn = "0169-5002",

publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - A case of dramatic reduction in cancer-associated thrombus following initiation of pembrolizumab in patient with a poor performance status and PD-L1+ lung adenocarcinoma harboring CCDC6–RET fusion gene and NF1/TP53 mutations

AU - Nakasuka, Takamasa

AU - Ohashi, Kadoaki

AU - Watanabe, Hiromi

AU - Kubo, Toshio

AU - Matsumoto, Shingo

AU - Goto, Koichi

AU - Hotta, Katsuyuki

AU - Maeda, Yoshinobu

AU - Kiura, Katsuyuki

N1 - Funding Information: This research received a specific grant from JSPS Grants-in-Aid for Scientific Research [Scientific Research (C): KAKEN 19K08625 to K. Ohashi and K. Kiura], and JSPS Grants-in-Aid for Scientific Research [Scientific Research (B): KAKEN 19H03667 to K. Ohashi and K. Kiura]. Publisher Copyright: © 2021 Elsevier B.V.

PY - 2021/6

Y1 - 2021/6

N2 - Objectives: Pembrolizumab is a standard treatment for non-small cell lung cancer (NSCLC) with high-PD-L1 expression; however, its effect is dismal in patients with poor physical condition. Additionally, the effect of immunotherapy is generally limited in NSCLC harboring driver mutations such asEGFR, ALK, or RET gene aberrations. Results: We report the beneficial effect of pembrolizumab in a patient with poor performance status and PD-L1+ lung adenocarcinoma with theCCDC6–RET fusion gene and co-occurring NF1/TP53 mutations, complicated by multiple cancer-associated thrombi and respiratory failure. Conclusions: Further studies are warranted to establish the role of co-occurring NF1/TP53 mutations as a positive predictive biomarker for pembrolizumab in NSCLC harboring RET fusion genes.

AB - Objectives: Pembrolizumab is a standard treatment for non-small cell lung cancer (NSCLC) with high-PD-L1 expression; however, its effect is dismal in patients with poor physical condition. Additionally, the effect of immunotherapy is generally limited in NSCLC harboring driver mutations such asEGFR, ALK, or RET gene aberrations. Results: We report the beneficial effect of pembrolizumab in a patient with poor performance status and PD-L1+ lung adenocarcinoma with theCCDC6–RET fusion gene and co-occurring NF1/TP53 mutations, complicated by multiple cancer-associated thrombi and respiratory failure. Conclusions: Further studies are warranted to establish the role of co-occurring NF1/TP53 mutations as a positive predictive biomarker for pembrolizumab in NSCLC harboring RET fusion genes.

UR - http://www.scopus.com/inward/record.url?scp=85104137576&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85104137576&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2021.03.022

DO - 10.1016/j.lungcan.2021.03.022

M3 - Article

C2 - 33845248

AN - SCOPUS:85104137576

SN - 0169-5002

VL - 156

SP - 1

EP - 4

JO - Lung Cancer

JF - Lung Cancer

ER -